Slides
Page 1
( basilea Shaping the Future of Infectious Diseases " Patients are at the heart of what we do❞ INVESTOR PRESENTATION August 05 , 2026
Page 2
2 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − Founded in 2000 as a spin off from Roche − Profitable Swiss commercial- stage biopharmaceutical company − About 190 employees − Headquarters in Allschwil, Switzerland, in the Basel area life sciences hub − Listed on the SIX Swiss Stock Exchange, Ticker: BSLN.SW Introducing Basilea and the executive management team Our experienced team brings deep expertise across Basilea's entire value chain.” DAVID VEITCH CEO ADESH KAUL CFO MARC ENGELHARDT MD, PH.D CMO GERRIT HAUCK PH.D. CTO LAURENZ KELLENBERGER PH.D. CSO 2014 2009 2010 2018 2000JOINED PREVIOUS ROLES "
Page 3
33 Creating anti-infective opportunities Our focus is on identifying and generating commercial opportunities in the anti-infectives area − We are focused on developing treatments for severe bacterial and fungal diseases − Unmet medical needs: − Therapies with limited spectrum of activity − Growing resistance − Lack of oral dosing forms − Toxicities − We strive to create sustainable value with meaningful benefits for patients and healthcare systems, generating long-term returns for investors and our partners − Currently two revenue generating hospital anti-infective brands: Cresemba® and Zevtera® Candida spp. Bloodstream, abdominal, osteoarticular, cardiac, ocular, CNS, pulmonary Aspergillus spp. Pulmonary, sinuorbital, CNS, cardiac, cutaneous, abdominal Fusarium spp. Bloodstream, cutaneous, sinuorbital, ocular, CNS, pulmonary Mucorales fungi Pulmonary, sinuorbital, CNS, renal, cutaneous, abdominal Staphylococci Bloodstream, cutaneous, cardiac, abdominal, osteoarticular, pulmonary Enterobacteriaceae Bloodstream, urinary, pulmonary, cutaneous, abdominal, osteoarticular Pseudomonas spp. Bloodstream, urinary, pulmonary Acinetobacter baumannii Bloodstream, urinary, pulmonary, cutaneous Manifestations of severe infections Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 4
4 Creating anti-infective opportunities Our business model Capital-efficient by design, asset-light where it matters In-license/acquire novel anti-infective assets Add value through clinical development File for regulatory approvals Manufacture/sell product through partnerships and more.. Eligible for royalties/ milestones from partners e.g. fosmanogepix and ceftibuten-ledaborbactam Value-sharing financial structures with limited upfront and development milestone payments Upside: non-dilutive funds/support from governments and non-profit organizations Identify commercial partner Lean and low risk commercialization model: limited selling expenses and no significant CAPEX Cashflow generating External pool of potential assets Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 5
5 Creating anti-infective opportunities Invasive fungal and severe bacterial infections are on the rise due to several factors Growing population of immunocompromised individuals (e.g. patients with chronic conditions) Aging population (e.g. elderly individuals more prone to infections) Increased use of immunosuppressive therapies (e.g. for organ or stem cell transplants, cancer therapies, biologic agents) Advances in medical procedures (e.g. medical devices like catheters or other foreign body materials) Increasing resistance against currently used antibiotics and antifungals Agriculture: widespread use of fungicides in agriculture Climate change (e.g. growing incidence of fungal infections) Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 6
6 Creating anti-infective opportunities Assets Preclinical Phase 1 Phase 2 Phase 3 Market COMMERCIAL Cresemba® isavuconazole Invasive aspergillosis and mucormycosis (US, EU and several other countries)¹ Aspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan) Zevtera® ceftobiprole Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries) Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) (United States) PHASE 3 Fosmanogepix USD ~1.0 bn peak sales potential Candidemia / invasive candidiasis (including Candida auris) Invasive mold infections (including invasive aspergillosis, fusariosis, lomentosporiosis, mucormycosis and other rare mold infections) Ceftibuten-ledaborbactam USD ~500 mn peak sales potential Complicated urinary tract infections (cUTI) PHASE 2 AND EARLIER BAL2062 Invasive aspergillosis BAL2420 (LptA inhibitor) Severe Enterobacteriaceae infections 1 The registration status and approved indications may vary from country to country. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Innovative anti-infective pipeline Addressing urgent and evolving infection threats
Page 7
7 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Capital efficiency through non-dilutive R&D funding ~ 440 by BARDA and CARB - X committed ~ 165 million in USD, rounding consistently applied million out of which awarded Non-dilutive funding has a long-term positive effect on value creation and risk mitigation: • Preserving shareholder value: No equity component; no dilution to shareholders • Increasing return-on-investment: Reducing Basilea’s share of investment • Reducing financial risk inherent during development: No repayment required
Page 8
8 Creating anti-infective opportunities Creating anti-infective opportunities Anti-infective pipeline Commercial portfolio
Page 9
9 Creating anti-infective opportunities Cresemba® — Differentiated by spectrum, safety and tolerability − Broad spectrum of activity against molds, including emerging molds (Mucorales fungi) − Consistent plasma levels − Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study − Can be administered without restriction in patients with renal impairment − Manageable drug-drug interaction profile − Once daily maintenance dose, IV/oral treatment − ECIL-6 guideline: Cresemba recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 10
10 Creating anti-infective opportunities Cresemba® Global commercial partnership Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution United States Canada Latin America Europe (excluding Nordics) Nordics MENA Region Asia-Pacific and China Japan 76 countries Marketed in MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026 100 MAT Q1/2022 MAT Q1/2024 MAT Q1/2024 MAT Q1/2025 MAT Q1/2026 In-market sales USD million782 April 2025 to March 2026 500 400 300 200 600 700 27% Year-on-Year Growth 800 900
Page 11
11 Creating anti-infective opportunities Creating anti-infective opportunities Cresemba® – Global market leader in terms of value Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Cresemba 26% USD 782 million Posaconazole 14% USD 427 million Caspofungin 13% USD 370 million Rezafungin 1% USD 35 million Continued growth opportunity for the brand: - Growth in the US until Q4 2027 - Growth in Europe until H2 2028 - Growth in Japan and other markets beyond 2028 * MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026, rounding consistently applied Voriconazole 14% USD 400 million Micafungin 6% USD 190 million Anidulafungin 7% USD 197 million liposomal amphotericin B 19% USD 571 million
Page 12
12 Creating anti-infective opportunities Zevtera® – Broad-spectrum hospital anti-MRSA cephalosporin − Single agent, first-line bactericidal therapy with proven efficacy in SAB, ABSSSI and CABP1, 2, 3 − Potential to replace antibiotic combinations − Strong activity against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA), with robust Gram-negative coverage − Low propensity for resistance development and cephalosporin-consistent safety profile1, 2, 3, 4 − USD 111 million BARDA product-specific funding, covering ~75% of costs of SAB and ABSSSI phase 3, regulatory and non-clinical activities5 − Commercialized in the US, China, selected countries in Europe, MENA and Canada 1 Syed YY. Drugs. 2014;74:1523-1542 and Basilea data on file. 2 Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517 3 Holland TL et al. N Engl J Med 2023;389:1390-1401 4 Rubino CM et al. Pediatr Infect Dis J. 2021;40:997-1003 5 Contract number HHSO100201600002C Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 12
Page 13
13 Creating anti-infective opportunities Focused on Growth and Innovation LOE: Loss of exclusivity; ROW: Rest Of World; NTAP: New Technology Add-On Payment Source: IQVIA Analytics Link, March 2026 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Zevtera launched in the US in July 2025 commercial partner: Innoviva Specialty Therapeutics − Important hospital formulary wins − Reimbursement: NTAP designation, Medicaid and 340B pricing, and J-code for outpatient billing − Repeat orders from major hospitals − US market exclusivity until April 2034 Zevtera® – Progress in US market access and initial positive clinical experience US market opportunity Daptomycin sales by region (2015, before LOE) ROW 3% Japan 2% EU top 5 6% US 89%
Page 14
14 Creating anti-infective opportunities Creating anti-infective opportunities Anti-infective pipeline Phase 3 programs
Page 15
15 Creating anti-infective opportunities Advancing our phase 3 programs towards approval Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Readout and regulatory process Ceftibuten-ledaborbactam: Phase 3 derisked through well-established phase 3 design Global phase 3 program in complicated urinary tract infections1 1 Includes pyelonephritis; 2 ClinicalTrials.gov ID: NCT05421858; 3 ClinicalTrials.gov ID: NCT06925321 FAST-IC: Global phase 3 in invasive candidiasis and candidemia2 FORWARD-IM: Global phase 3 in invasive mold infections3 Readout and regulatory process Fosmanogepix: Phase 3 derisked through positive real-world data 2024 2025 2026 2027 2028 2029
Page 16
16 Creating anti-infective opportunities Fosmanogepix First-in-class broad-spectrum antifungal − Novel mode of action leading to fungal cell death and reduced fungal pathogenicity − Developed for difficult-to-treat infections, including resistant fungi − Active against most clinically relevant molds and yeasts − Wide tissue distribution, including difficult-to- reach sites such as central nervous system (CNS) − IV and oral formulations − Phase 3 studies ongoing in invasive candidiasis and in invasive mold infections − QIDP, Fast Track1 & Orphan Drug Designations, enabling accelerated review and extended market exclusivity Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 1 QIDP and Fast Track designations by the FDA for invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis, and coccidioidomycosis
Page 17
17 Creating anti-infective opportunities Adapted from Hoenigl M, Sprute R, Egger M et al. Drugs. 2021;81:1703-1729. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Fosmanogepix – Potent broad-spectrum activity * including C. albicans, C. auris, C. dubliniensis, C. glabrata, C. krusei, C. lusitaniae, C.parapsilosis, C. tropicalis. Fosmanogepix not active against C. krusei. † including A. calidoustus, A. fumigatus (including azole-resistant), A. flavus, A. lentulus, A. nidulans, A. niger, A. terreus, A. tubingensis. ‡ including Cunninghamella spp., Lichtheimia spp., Mucor spp., Rhizopus spp. § including Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum. ‖ including Alternaria alternata, Cladosporium spp. Paecilomyces variotii, Purpureocillium lilacinum, Scopulariosis spp., Rasamsonia spp. ¶ including Trichosporon asahii, Exophiala dermatitidis, Malassezia furfur. IV and Oral Oral Oral IV Fungal pathogens Candida spp.* Aspergillus spp.† Mucorales‡ Fusarium spp. Scedosporium spp. Lomentospora spp. Cryptococcus spp. Endemic molds§ Other rare molds‖ Other rare yeasts¶ Potent activity Variable activity No activity Unknown
Page 18
18 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − For patients with serious and/or life-threatening invasive fungal infections and no other available treatment option (NCT06433128) − Patients who progressed on standard-of- care treatment, developed treatment- limiting toxicity, or with resistant fungal pathogens − Program started in 2020 − More than 500 patients from 22 countries to date − In the context of the 2023 Fusarium meningitis outbreak in US/Mexico, fosmanogepix was recommended as therapy by the US Centers for Disease Control and Prevention (CDC), due to potent activity against Fusarium spp. Supportive real-world evidence from a global expanded access program Status on 31 December 2025 Calendar year Number of new patients treated per year Number of countries (1) (2) (2) (5) (11) (20)
Page 19
19 Creating anti-infective opportunities 1 Ledaborbactam restores ceftibuten activity against Enterobacterales producing Ambler Class A, C and D ESBLs and carbapenemases (including pathogens designated as critical threats in the WHO Priority Pathogen List, 2024; 2 Flores-Mireles AL, et al. Nat Rev Microbiol. 2015;13(5):269-84; 3 Marantidis J, Sussman RD. Infect Drug Resist. 2023;16:1391-1405; 4 Lodise TP, et al. Open Forum Infect Dis. 2022;9(7):ofac315. Ceftibuten-ledaborbactam Targeting resistant Gram-negative bacteria − Combines ceftibuten, an established beta-lactam (BL) antibiotic with ledaborbactam, a novel beta-lactamase inhibitor (BLI) restoring ceftibuten activity in resistant bacteria − Developed to provide an oral BL/BLI treatment option for resistant pathogens − Oral bioavailability reduces the use of IV antibiotics, resulting in less hospitalizations and earlier hospital discharges − Active against Gram-negative bacteria including multidrug-resistant pathogens such as extended spectrum beta-lactamase (ESBL) producers and carbapenem-resistant Enterobacterales (CRE)1 − Gram-negative bacteria, particularly uropathogenic Escherichia coli (E. coli), are a leading cause of complicated urinary tract infections (cUTI)2,3,4 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 20
20 Creating anti-infective opportunities Ceftibuten-ledaborbactam – Oral treatment for patients with complicated urinary tract infections *Reminder: Antibiotics sales typically peak around loss of exclusivity (LOE), which has not yet been reached. Basilea’s ceftibuten-ledaborbactam presents a significant commercial opportunity − An oral treatment option for patients with cUTI − Potential to simplify cUTI treatment and reduce hospitalization − Complementary to existing IV therapies − QIDP and Fast Track designations1 by the FDA1 − Phase 3 program in cUTI to initiate in early 2027 1 QIDP and Fast Track designations by the FDA for cUTI and uncomplicated urinary tract infections. Source: IQVIA Analytics Link, March 2026 Avycaz (ceftazidime-avibactam) Global sales about USD 722 million* Fetroja (cefiderocol) Global sales about USD 319 million* Zerbaxa (ceftolozane/tazobactam) Global sales about USD 304 million* Commercial success of newer Gram-negative IV-only antibiotics: Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 21
21 Creating anti-infective opportunities Creating anti-infective opportunities Anti-infective pipeline Early-stage programs
Page 22
22 Creating anti-infective opportunities BAL2062 – For the treatment of invasive aspergillosis − First-line IV treatment of invasive aspergillosis (incl. azole-resistant) with the potential to deliver superior efficacy vs. standard-of-care − Rapidly fungicidal with a new mode of action − Safe and well tolerated in a phase 1 study − No expected drug–drug interactions (DDIs) and no renal toxicity − No cross-resistance − Regulatory discussions ongoing in 2026 to define phase 2 and phase 3 clinical development pathways Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 23
23 Creating anti-infective opportunities BAL2420 (LptA inhibitor) Next generation first-in-class antibacterial − Bactericidal with novel mode of action targeting the lipopolysaccharide transport protein A (LptA) of Gram-negative bacteria − Potential new treatment option for the most frequent Gram-negative pathogens causing infections (Enterobacteriaceae), including carbapenem-resistant isolates − No cross-resistance to other antibiotic classes − First-in-human phase 1 clinical study1 evaluating the safety, tolerability, and pharmacokinetics was initiated in Q1 2026 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 1 ClinicalTrials.gov ID: NCT07500181
Page 24
24 Creating anti-infective opportunities Financials & Outlook
Page 25
25 Creating anti-infective opportunities Note: Consolidated figures in conformity with US GAAP; rounding applied consistently Strong financial results FY 2025 – Surpassed financial guidance in CHF million FY 2024 FY 2025A (FY 2025 guidance) Cresemba and Zevtera related revenue of which royalty income of which milestone and upfront payments Other revenue 194.8 96.7 40.4 13.7 194.4 111.6 32.0 38.0 (190) (110) (35) Total revenue 208.5 232.4 (225) Cost of products sold Operating expenses 38.7 108.7 39.3 141.5 Operating profit 61.2 51.5 (50) Net profit 77.6 40.2 Cash and cash equivalents and restricted cash 124.6 162.3 Convertible senior unsecured bonds 95.9 75.4 Net cash (as of December 31, 2024/2025) 28.6 86.9 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 26
26 Creating anti-infective opportunities -79.2 -63.8 -54.1 -32.0 7.1 14.2 74.4 62.1 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Strong cash flows after making significant R&D investments Cash flows from operating activities (in CHF million) Note: Consolidated figures in conformity with US GAAP; rounding applied consistently 20232022 2021202020192018 20252024 Including CHF 12 million upfront and milestone payments for in- licensing ceftibuten- ledaborbactam
Page 27
27 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 01.01.202601.01.2022 01.01.2023 0 50 100 150 200 250 01.01.2025 CHF 49 mn CHF 75 mn CHF 21 mn Athyrium loan 2022 convertible bonds 2027 convertible bonds Strengthening the balance sheet through debt reduction CHF 145 million (mn) debt reduction between 2022-2025 (nominal value) 221 172 97 76
Page 28
28 Creating anti-infective opportunities Note: Consistent rounding was applied. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution FY 2026 financial guidance – Increasing revenue and operating profit while progressing the R&D portfolio in CHF million FY 2026 (guidance) FY 2025 (actuals) Cresemba and Zevtera related revenue ~200 194.4 of which royalty income ~120 111.6 Total revenue ~ 10% increase 232.4 Research and development expenses ~ 20% increase 105.9 Operating profit ~ 20% increase 51.5
Page 29
29 Creating anti-infective opportunities 65.0 78.9 96.7 111.6 24.7 33.5 40.4 32.0 32.7 37.9 57.8 50.8 0.0 50.0 100.0 150.0 200.0 250.0 2022 2023 2024 2025 2026E Cresemba and Zevtera related revenue Revenue mix shifting towards higher margin royalties and milestones - increasing cash contribution Royalties (estimated) Milestones (estimated) Product revenue (estimated) in CHF million Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution ~45 ~35 ~120 Royalties Milestones Product revenue
Page 30
30 Creating anti-infective opportunities 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Commercial portfolio outlook beyond 2026 Current phase 3 pipeline has the potential to double 2025 in-market sales Cresemba Fosmanogepix Ceftibuten-ledaborbactam Ceftibuten- ledaborbactam launch Zevtera US launch Fosmanogepix launch Zevtera
Page 31
31 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution “Agenda 2030” Basilea well positioned for sustainable growth Strong financial position − CHF 160 million cash as of end-2025 − Approx. CHF 600 million cumulative cash flow from Cresemba and Zevtera from 2026 to 2030 − More than USD 350 million potential non-dilutive funding from existing agreements (awarded and potential future tranches) from 2026 to 2030 − Bring phase 3 programs to market with the potential to double current in-market sales − Advance early-stage pipeline − In-license or acquire exciting new assets *Potential upsides: later than expected Cresemba generic entry in the US and Europe, new non- dilutive funding agreements, and first revenues from fosmanogepix and ceftibuten-ledaborbactam This allows us to
Page 32
32 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Investing in Basilea Pharmaceutica 1 Profitable commercial-stage company with two marketed anti-infective products 2 Strong financial position with sustainable cash flows supporting continued growth 3 Leading strategic position in an area of high unmet medical need, addressing rising challenges in treating severe bacterial and fungal infections 4 Current phase 3 pipeline assets alone creates opportunity to double 2025 in-market sales 5 Proven, capital-efficient and asset-light business model with low operational expenses, non-dilutive funding, and strong global partnerships
Page 33
33 Creating anti-infective opportunities Disclaimer and forward-looking statements This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward- looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 34
34 Creating anti-infective opportunities Save the date Capital Markets Day October 28, 2026 Zurich, Switzerland
Page 35
Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil | Switzerland Phone +41 61 606 1102 E-mail investor_relations@basilea.com
Page 36
Glossary − ABSSSI Acute bacterial skin and skin structure infections − BARDA Biomedical Advanced Research and Development Authority − BL/BLI Beta-lactam/Beta-lactamase inhibitor − CABP Community-acquired bacterial pneumonia − CARB-X Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator − CDC US Centers for Disease Control and Prevention − CHF Swiss Franc − CAPEX Capital Expenditures − CRE Carbapenem Resistant Enterobacterales − cUTI Complicated Urinary Tract Infections − DDI Drug–Drug Interaction − EMA European Medicines Agency − ESBL Extended spectrum beta-lactamase − EU European Union − FDA US Food and Drug Administration − FY Full Year Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution − HABP Hospital-acquired bacterial pneumonia − IV Intravenous − LOE Loss of Exclusivity − MAT Moving Annual Total − MENA Middle East and North Africa − Mn Million − NIM Non-inferiority margin − MRSA Methicillin-resistant Staphylococcus aureus − MSSA Methicillin-susceptible Staphylococcus aureus − NTAP New Technology Add-On Payment − OTA Other Transaction Agreement − QIDP Qualified Infectious Disease Product − R&D Research and Development − ROW Rest Of World − SAB Staphylococcus aureus bacteremia − US United States − US GAAP United States Generally Accepted Accounting Principles − USD United States Dollar
Page 37
37 Creating anti-infective opportunities All rights reserved. © 2026 Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland info@basilea.com www.basilea.com Shaping the Future of Infectious Diseases
Page 38
Appendix Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution
Page 39
39 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Commercially successful hospital antifungals have achieved peak sales of ~ 600-900 USD million − Sales of branded antifungals typically peak around the time of their loss of exclusivity (more than 10 years market opportunity) − Basilea’s Cresemba is already today achieving ~USD 780 million annual sales with continued strong double-digit year on year growth 2010*Vfend 2002 Noxafil 2005 Cancidas Mycamine 2001 2002 Product launch Sales (USD million) 0 100 200 300 400 500 600 700 800 *peak year Pfizer Inc., 2010 Financial Report, page 25 Merck & Co., Inc., Commission File No. 1-6571, page 124 Merck & Co., Inc., Commission File No. 1-6571, page 43 Astellas Pharma Inc., IFRS, Financial results for the fiscal year 2017 (FY2017), page 6 825 742 681 371 2018* 2014* 2016*
Page 40
40 Creating anti-infective opportunities Europe (Pfizer)US (Astellas) Basilea’s revenues from Cresemba by geography 65% generated outside of the US Cresemba generics timing: − US: Generics impact expected from Q4 2027 − Europe: Generics impact expected from H2 2028 Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution ROW (Distributors)*Japan (Asahi) *Assuming 90% of Distributors revenue attributed to Cresemba Geographic revenue distribution (2025) APAC (Pfizer) 42% 11% 35% 12%
Page 41
41 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution ~450 adults with invasive candidiasis/ candidemia Caspofungin IV Randomization 2:1 Fosmanogepix Oral Fluconazole Oral Primary Endpoints FDA: Survival at day 30 EMA: Overall Response at end-of-study treatment (up to day 42) Treatment duration up to 6 weeks Primary aim: demonstrate non-inferiority to caspofungin / fluconazole (15% NIM) A randomized, double-blind phase 3 study of fosmanogepix for the treatment of adult patients with invasive candidiasis including candidemia1 Optional IV to oral switch from day 6 onwards Global phase 3 study in invasive candidiasis 1 ClinicalTrials.gov ID: NCT05421858 EMA: European Medicines Agency; FDA: Food and Drug Administration (USA); IV: intravenous; NIM: non-inferiority margin. Fosmanogepix IV
Page 42
42 Creating anti-infective opportunities Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution Fosmanogepix IV with optional oral switch Best available antifungal treatment Fosmanogepix IV with optional oral switch Global phase 3 study in invasive mold infections A randomized, open-label phase 3 study of fosmanogepix for the treatment of adult patients with invasive mold infections1 Randomization 2:1 Cohort A – primary therapy ~160 patients in 4 sub-cohorts Cohort B – salvage therapy ~60 patients 1. Aspergillus spp. 2. Fusarium spp. 3. Lomentospora prolificans 4. Mucorales fungi Patients infected with Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant mold, who developed intolerance, toxicities, lack of clinical response, or whose fungal isolate is resistant to standard-of-care therapy Primary endpoint: Day 42 all-cause mortality Treatment duration up to 180 days 1 ClinicalTrials.gov ID: NCT06925321.
Page 43
43 Creating anti-infective opportunities Complicated urinary tract infections: Resistant Enterobacterales pathogens drive opportunity − cUTIs are urinary tract infections extending beyond the bladder, accompanied by local and systemic symptoms − cUTIs are among the most common bacterial infections in both hospital and community settings − Associated with considerable morbidity and healthcare resource utilization − Gram-negative bacteria, particularly uropathogenic Escherichia coli (E. coli), are a leading cause of cUTI1,2 − Significant proportion of Enterobacterales (e.g., E. coli) are multi-drug-resistant and/or ESBL producing2 Pathogen distribution in cUTI3 Adapted from Flores-Mireles et al. Nat Rev Microbiol. 2015;13(5):269-84. 75% Enterobacterales Gram-positives 16% Candida spp. 7% P. aeruginosa 2% 1 Flores-Mireles AL, et al. Nat Rev Microbiol. 2015;13(5):269-84; 2 Marantidis J, Sussman RD. Infect Drug Resist. 2023;16:1391-1405; 3 Lodise TP, et al. Open Forum Infect Dis. 2022;9(7):ofac315. Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution